Rimegepant

(preventative)

Atogepant (preventative)

STOP if less than 50% reduction in headache days.

STOP if less than 50% reduction in headache days.

12 weeks initial treatment.

1. STOP in episodic if less than 50% reduction in headache days.
2. STOP in chronic migraine if less than 30% reduction in headache days

Formulary status

Primary care/GP initiation, prescribing and monitoring

Secondary care/Community Specialist initiation and continuation

(pending for atogepant)

Chronic Migraine (Prophylaxis (15 or more headache days a month, 8 with migraine symptoms))

No

No

Yes

Episodic Migraine - High frequency (Prophylaxis - more than 4 and fewer than 15 headache days a month)

N/A

Yes

Yes

Acute migraine rescue

Yes (Triptans contraindicated and NSAIDs and paracetamol tried but ineffective)

N/A

No

Secondary care/Community Specialist initiation

Yes

Yes

Yes

GP initiation

Yes

No

Pending

Secondary care/Community Specialist monitoring

Yes

Yes

Pending

GP monitoring

Yes

No

Pending

Blueteq availability* (GP surgery/primary care)

No

No

No

Blueteq availability* (secondary care/community specialist  providers)

No

Yes

Yes

ICB approved to use

Yes

Yes

Pending (approved use currently in secondary care only)

Homecare availability in GP surgery/primary care

No

No

No

Homecare availability (secondary care/community specialist  providers)

No

Yes

Yes